Heidelberg Pharma AG (GB:0QW5)
LSE:0QW5
0QW5 Stock Chart & Stats
€2.39
€0.04(1.64%)
At close: 4:00 PM EST
€2.39
€0.04(1.64%)
Day’s Range― - ―
52-Week Range€2.32 - €4.95
Previous CloseN/A
Volume39.00
Average Volume (3M)150.00
Market Cap
€120.70M
Enterprise Value€115.73M
Total Cash (Recent Filing)€9.26M
Total Debt (Recent Filing)€77.40K
Price to Earnings (P/E)―
Beta0.54
Next Earnings
Jul 15, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.86
Shares Outstanding46,784,317
10 Day Avg. Volume67
30 Day Avg. Volume150
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)-12.31
Price to Sales (P/S)92.22
P/FCF Ratio-4.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.06
Revenue Forecast (FY)€12.90M
Bulls Say, Bears Say
Bulls Say
Proprietary ATAC PlatformOwning a proprietary ATAC antibody‑drug conjugate platform provides a durable scientific moat: it enables multiple internal programs, creates potential for out‑licensing or partnerships, and concentrates R&D know‑how that can produce multiyear value beyond single trials.
Lower Reported Debt (2025)Reduced reported debt in 2025 lessens near‑term refinancing pressure and can extend strategic optionality. Lower leverage improves ability to pursue partnerships, negotiate non‑dilutive deals, or time equity raises, supporting operational continuity over several quarters.
Ability To Generate Gross ProfitHistorical periods of healthy gross profit indicate the core technology and program economics can deliver positive product‑level margins. If operating costs are controlled, this structural gross‑profit capability supports a credible path to sustainable margins as programs commercialize or scale.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flow is a durable risk: it forces reliance on external financing or partner funding, increases dilution risk, and constrains the firm’s ability to fund clinical programs independently over the medium term without material capital raises.
Negative Shareholders' EquityStockholders’ equity turning negative is a structural red flag that reduces financial flexibility, can trigger covenant and counterparty concerns, and raises insolvency perception. It narrows strategic choices and elevates the cost and difficulty of obtaining non‑dilutive capital.
Ongoing Large Losses; Declining RevenueSustained operating and net losses combined with falling revenue undermine the path to profitability and heighten dependence on external funding. This structural earnings weakness erodes runway, complicates long‑term planning, and weakens bargaining power with partners and investors.
0QW5 FAQ
What was Heidelberg Pharma AG’s price range in the past 12 months?
Heidelberg Pharma AG lowest share price was €2.32 and its highest was €4.95 in the past 12 months.
What is Heidelberg Pharma AG’s market cap?
Heidelberg Pharma AG’s market cap is €120.70M.
When is Heidelberg Pharma AG’s upcoming earnings report date?
Heidelberg Pharma AG’s upcoming earnings report date is Jul 15, 2026 which is in 31 days.
How were Heidelberg Pharma AG’s earnings last quarter?
Heidelberg Pharma AG released its earnings results on Mar 26, 2026. The company reported -€0.091 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.091.
Is Heidelberg Pharma AG overvalued?
According to Wall Street analysts Heidelberg Pharma AG’s price is currently Overvalued.
Does Heidelberg Pharma AG pay dividends?
Heidelberg Pharma AG does not currently pay dividends.
What is Heidelberg Pharma AG’s EPS estimate?
Heidelberg Pharma AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Heidelberg Pharma AG have?
Heidelberg Pharma AG has 46,784,317 shares outstanding.
What happened to Heidelberg Pharma AG’s price movement after its last earnings report?
Heidelberg Pharma AG reported an EPS of -€0.091 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 6.786%.
Which hedge fund is a major shareholder of Heidelberg Pharma AG?
Currently, no hedge funds are holding shares in GB:0QW5
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Heidelberg Pharma AG Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
―
20 days / 200 days
Momentum
5.61%
12-Months-Change
Fundamentals
Return on Equity
-5460.56%
Trailing 12-Months
Asset Growth
-41.71%
Trailing 12-Months
Company Description
Heidelberg Pharma AG
Heidelberg Pharma AG is a biopharmaceutical firm dedicated to oncology, with a specific emphasis on its innovative antibody-targeted amanitin conjugates (ATAC) technology. The company conducts its activities across Germany, various other European countries, the United States, and globally. Its primary drug candidate, HDP-101, is presently in Phase I/IIa clinical trials for individuals suffering from relapsed or refractory multiple myeloma. The pipeline also features several other ATAC compounds: HDP-102 is being developed for non-Hodgkin lymphoma; HDP-103 targets metastatic castration-resistant prostate cancer; HDP-104 is aimed at various tumor types; and HDP-XX addresses both solid and hematological tumors. Further development programs include MGTA-ATACs, designed for hematopoietic stem cells (HSCs) and conditioning treatments for blood cancers and genetic conditions, alongside TAK-ATACs for broader oncology use. Heidelberg Pharma's offerings extend to diagnostic and therapeutic antibodies. TLX250-CDx, a diagnostic antibody for imaging purposes, is in Phase III for renal cancer, Phase I for urothelial carcinoma (bladder cancer), and Phase II for triple-negative breast cancer. Additionally, TLX250 (girentuximab), a therapeutic antibody, is undergoing Phase II evaluation for patients with advanced clear cell renal cell carcinoma. The company's diverse portfolio is complemented by RHB-107, an oral serine protease inhibitor in Phase II/III studies for both COVID-19 and advanced cholangiocarcinoma, as well as LH011 for pancreatic cancer. A significant licensing agreement and strategic partnership with Huadong Medicine Co., Ltd. grants the latter development and commercialization rights for HDP-101 and HDP-103 throughout Asia. Established in Ladenburg, Germany, in 1997, the company was formerly known as Wilex AG before rebranding to Heidelberg Pharma AG in October 2017.
Technical Analysis
―
B.R.A.I.N. Biotechnology Research and Information Network
―
co.don AG
―
Medigene
―
Formycon AG
―